# DARE catalysts: Dare Bioscience, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/dare/catalysts

> Dare Bioscience, Inc. (DARE) has 3 upcoming catalysts. The next is the Revatio® (sildenafil) topline data readout, 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only, year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for DARE?

Dare Bioscience, Inc. (DARE) has 3 upcoming catalysts. The next is the Revatio® (sildenafil) topline data readout, 2027. Press release filed with the SEC (EX-99): "Topline results are expected in 2027." [Calendar and source filings](https://sec-api.dev/companies/dare/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001493152-26-037737, https://www.sec.gov/Archives/edgar/data/1401914/000149315226037737/ex99-1.htm (retrieved 2026-11-12). Last confirmed 2026-08-13. Cite: https://sec-api.dev/companies/dare/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Dare Bioscience, Inc. |
| Ticker | DARE (Nasdaq) |
| SEC CIK | 1401914 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/dare |

## Cash runway

Cash $12.6M as of 2026-06-30; quarterly burn $6.8M; about 5.6 months of runway at that rate (XBRL company facts, accession 0001401914-26-000043).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Apr 2023 | [Revatio® (sildenafil) trial start](https://sec-api.dev/pdufa/sildenafil) | DARE |  | completed | "In April 2023, we initiated subject enrollment in a Phase 1, single-dose, double-blind, placebo-controlled, 3-way crossover clinical study of Sildenafil Cream using thermography to assess the PD and pharmacokinetic (PK) characterization of Sildenafil Cream." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1401914/000140191426000004/dare-20251231.htm)) |
| Dec 2023 | [Ovaprene (ovaprene) trial start](https://sec-api.dev/pdufa/ovaprene) | DARE |  | completed | "National Institutes of Health (NIH) and commercial collaborator Bayer, Daré commenced patient enrollment in the Ovaprene® pivotal Phase 3 clinical study in December 2023." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1401914/000149315224045860/ex99-1.htm)) |
| November 14, 2024 | [Dare Bioscience, Inc. earnings report](https://sec-api.dev/companies/dare/catalysts) | DARE |  | completed | "Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1401914/000149315224045860/ex99-1.htm)) |
| Mar 2025 | [Dare Bioscience, Inc. FDA approval](https://sec-api.dev/companies/dare/catalysts) | DARE |  | completed, approved | "In March 2025, the Company announced that it was expanding its business strategy to include Section 503B compounding as a dual-path approach to bring certain of its proprietary formulations to market as soon as practicable while it continues to pursue FDA approval of its product candidates." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1401914/000140191425000022/dare-20250331.htm)) |
| March 31, 2025 | [Dare Bioscience, Inc. earnings report](https://sec-api.dev/companies/dare/catalysts) | DARE |  | completed | "Bioscience Reports Full Year 2024 Financial Results and Provides Company Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1401914/000164117225001682/ex99-1.htm)) |
| mid-2025 | [Revatio® (sildenafil) trial start](https://sec-api.dev/pdufa/sildenafil) | DARE |  | scheduled | "Phase 3 clinical study of Sildenafil Cream in premenopausal women with FSAD, reflecting the FDA's recommendations, to the FDA in the first quarter of 2025, and that we are targeting mid-2025 for commencement of the Phase 3 study." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1401914/000149315224050117/form8-k.htm)) |
| May 13, 2025 | [Dare Bioscience, Inc. earnings report](https://sec-api.dev/companies/dare/catalysts) | DARE |  | completed | "Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1401914/000164117225009939/ex99-1.htm)) |
| Jul 2025 | [Ovaprene (ovaprene) interim data readout](https://sec-api.dev/pdufa/ovaprene) | DARE |  | completed, positive | "July 2025, Daré announced positive interim data from the ongoing open-label Phase 3 trial of Ovaprene (ClinicalTrials.gov" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1401914/000149315225025491/ex99-1.htm)) |
| Jul 2025 | [Revatio® (sildenafil) interim data readout](https://sec-api.dev/pdufa/sildenafil) | DARE |  | scheduled | "Review of interim data by the study's data safety monitoring board, an independent group of experts which evaluates the safety and integrity of the study, scheduled for July 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1401914/000164117225009939/ex99-1.htm)) |
| August 14, 2025 | [Dare Bioscience, Inc. earnings report](https://sec-api.dev/companies/dare/catalysts) | DARE |  | completed | "Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1401914/000164117225023971/ex99-1.htm)) |
| November 13, 2025 | [Dare Bioscience, Inc. earnings report](https://sec-api.dev/companies/dare/catalysts) | DARE |  | completed | "Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1401914/000149315225022277/ex99-1.htm)) |
| 2026 | [Dare Bioscience, Inc. topline data readout](https://sec-api.dev/companies/dare/catalysts) | DARE |  | scheduled | "Daré currently anticipates enrollment to complete in 2026, which would put a 2027 topline data readout within reach and advance the potential premarket approval (PMA) pathway for what has the potential to be the first non-implanted, non-hormonal monthly contraceptive option on the market." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1401914/000149315226012902/ex99-1.htm)) |
| March 26, 2026 | [Dare Bioscience, Inc. earnings report](https://sec-api.dev/companies/dare/catalysts) | DARE |  | completed | "Bioscience Reports Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1401914/000149315226012902/ex99-1.htm)) |
| May 14, 2026 | [Ovaprene (ovaprene) earnings report](https://sec-api.dev/pdufa/ovaprene) | DARE |  | completed | "Daré Bioscience Reports First Quarter 2026 Financial Results and Provides Business Update Your publication date and time will appear here. \| Source: Daré Bioscience, Inc. Company Highlights Second Positive DSMB Review of Interim Data from Ovaprene® Phase 3 Clinical Trial, DARE to PLAY™ Anticipated Dispensing Commencement and Flora Sync LF5™ Commercial Launch Summer 2026; First Product Revenue Expected in June 2026; Call Hosted During National Women's Health Week." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1401914/000140191426000025/a260514q12026earningsupd.htm)) |
| August 13, 2026 | [Dare Bioscience, Inc. earnings report](https://sec-api.dev/companies/dare/catalysts) | DARE |  | completed | "Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women's Health Strategy Advances" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1401914/000149315226037737/ex99-1.htm)) |
| 2027 | [Revatio® (sildenafil) topline data readout](https://sec-api.dev/pdufa/sildenafil) | DARE |  | scheduled | "Topline results are expected in 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1401914/000149315226037737/ex99-1.htm)) |
| October 2027 | [Lopinavir / ritonavir primary completion](https://sec-api.dev/pdufa/lopinavir-ritonavir) | DARE | Human Papilloma Virus (HPV); High-risk Human Papillomavirus Infection | scheduled | "NCT07601074 (A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor Daré Bioscience, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07601074)) |
| Oct 2027 to Jan 2028 | [Lopinavir / ritonavir topline data readout](https://sec-api.dev/pdufa/lopinavir-ritonavir) | DARE | Human Papilloma Virus (HPV); High-risk Human Papillomavirus Infection | scheduled | "NCT07601074 (A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor Daré Bioscience, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07601074)) |

## Drugs

- [Lopinavir / ritonavir](https://sec-api.dev/pdufa/lopinavir-ritonavir): Human Papilloma Virus (HPV)
- [Ovaprene (ovaprene)](https://sec-api.dev/pdufa/ovaprene): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/dare/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "DARE catalysts: Dare Bioscience, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/dare/catalysts

```bibtex
@misc{secapidev_companies_dare_catalysts_20261116,
  title        = {DARE catalysts: Dare Bioscience, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/dare/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_dare_catalysts_20261116","title":"DARE catalysts: Dare Bioscience, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/dare/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
